Astrazeneca (AZN) Non-Current Assets (2009 - 2026)

Astrazeneca has reported Non-Current Assets for 18 years, with the latest figure at $87.9 billion in Q2 2026.

• On a quarterly basis, Non-Current Assets rose 5.25% year-over-year to $87.9 billion in Q2 2026; TTM through Jun 2026 was $87.9 billion, a 5.25% increase from a year earlier, with the FY2025 full-year figure at $85.4 billion, up 9.13% from the prior year.
• Non-Current Assets was $87.9 billion for Q2 2026 at Astrazeneca, up from $84.4 billion in the prior quarter.
• The five-year high for Non-Current Assets was $87.9 billion in Q2 2026, with the low at $73.6 billion in Q3 2023.
• Average Non-Current Assets over 5 years is $78.8 billion, with a median of $77.9 billion recorded in 2022.
• The largest YoY upside for Non-Current Assets was 68.05% in 2022 against a maximum downside of 8.16% in 2022.
• Over 5 years, Non-Current Assets stood at $73.9 billion in 2022, then gained by 2.94% to $76.1 billion in 2023, then grew by 2.82% to $78.2 billion in 2024, then rose by 9.13% to $85.4 billion in 2025, then rose by 2.95% to $87.9 billion in 2026.
• The last three Non-Current Assets figures came in at $87.9 billion (Q2 2026), $84.4 billion (Q1 2026), and $85.4 billion (Q4 2025), per Business Quant data.